Enanta Pharmaceuticals, Inc. (ENTA) SEC Filings & Earnings Calls

HCV Royalty Concentration

“Our royalty revenue is generated through our Collaborative Development and License Agreement with AbbVie... substantially all of our royalty revenue has been derived from AbbVie's net sales of MAVYRET/MAVIRET.” · word for word

Clinical Trial Uncertainty

“Given the uncertainty associated with clinical trial enrollments and the risks inherent in the development process, we are unable to determine the duration and completion costs of the current or future clinical trials of our product candidates or if, or to what extent, we will generate revenue from the commercialization and sale of any of our product candida” · word for word

No Product Revenue

“As our internal product candidates are currently in preclinical or clinical development, we have not generated any revenue from our own product sales. We do not expect to generate any revenue from product sales derived from these product candidates for at least the next several years.” · word for word

Revenue concentration on single royalty stream from AbbVie's HCV drug; declining sales trend.

“Revenue decrease primarily due to AbbVie's lower reported HCV sales.”

No approved products; clinical-stage pipeline with regulatory and trial risk.

“Clinical-stage biotechnology company; no approved antiviral therapies for RSV currently available.”

Dilution risk from potential sale of up to $75M in common stock.

“Corporation may offer and sell Shares having an aggregate offering price of up to $75,000,000.” · word for word

Patent invalidity eliminates potential future royalty stream from Paxlovid; no immediate cash impact but opportunity cost.

“Court affirmed invalidity of claims of the '953 Patent.”

Clinical development risk; no approved RSV treatment yet; regulatory and commercial uncertainty

“Forward-looking statements about clinical development plans and market potential are subject to risks and uncertainties.”

Dependence on AbbVie HCV royalty revenue

“Our royalty revenue is generated through our Collaborative Development and License Agreement with AbbVie... substantially all of our royalty revenue has been derived from AbbVie's net sales of MAVYRET/MAVIRET.” · word for word

Clinical trial risk

“Our internal product candidates are currently in pre-clinical or clinical development, we have not generated any revenue from our own product sales.” · word for word

Patent litigation risk

“Costs associated with prosecuting our patent infringement litigation regarding use of a coronavirus 3CL protease inhibitor in Paxlovid, Pfizer's antiviral treatment for COVID-19.” · word for word

Dependence on AbbVie royalty revenue

“Revenue entirely from AbbVie's MAVYRET/MAVIRET sales; 54.5% of royalty paid to OMERS until 2032.”

No approved products; pipeline risk

“Company is clinical-stage; no marketed products; all programs in development.”

Patent litigation outcome uncertain; potential damages if successful, but no guarantee.

“Company seeking damages for patent infringement; appeal scheduled.”

Potential dilution from increased share reserve for equity incentives.

“increase the number of shares reserved for issuance thereunder by 1,600,000 shares” · word for word

Clinical development risk

“Our research and drug discovery and development programs are in early stages; therefore, the successful development of our product candidates is highly uncertain and may not result in approved products.” · word for word

Revenue concentration risk

“Our royalty revenue is generated through our Collaborative Development and License Agreement with AbbVie... substantially all of our royalty revenue has been derived from AbbVie’s net sales of MAVYRET/MAVIRET.” · word for word

Patent litigation risk

“Costs associated with prosecuting our patent infringement litigation regarding use of a coronavirus 3CL protease inhibitor in Paxlovid, Pfizer's antiviral treatment for COVID-19.” · word for word

Clinical-stage biotech with no approved products; relies on royalty revenue and pipeline success

“Net loss of $11.9 million; R&D expenses of $20.9 million; no product revenue.”

Equity dilution from share increase

“The proposed increase of 1,600,000 shares, which represents the equivalent of 5.5% of our shares of common stock outstanding as of December 31, 2025” · word for word

Dependence on equity for retention

“The Compensation Committee believes that the proposed addition to the share reserve is essential to the Company’s ability to continue to grant equity incentives for at least the next year, which is vital to our efforts to retain the highly skilled individuals required to support our continued growth” · word for word

HCV royalty concentration

“Our royalty revenue is generated through our Collaborative Development and License Agreement with AbbVie” · word for word

Clinical trial failure risk

“The successful development of our product candidates is highly uncertain and may not result in approved products.” · word for word

Cash burn risk

“We have incurred losses in each year since our inception and we expect to continue to incur losses for the foreseeable future.”

Dependence on AbbVie HCV royalty revenue; revenue decline in FY2025 due to lower AbbVie sales.

“Revenue decrease year-over-year due to decline in AbbVie's sales of MAVYRET/MAVIRET in first nine months.”

Ongoing net losses and negative earnings per share; cash burn continues.

“Net loss of $81.9M for FY2025; cash position $188.9M but funded by debt and royalty sale.”